Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: November 16, 2023
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering and concurrent private placement of warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 1,139,063 shares of Common Stock at $0.64 per share.
- Warrant Issuance: Concurrent issuance of unregistered warrants to purchase 1,139,063 shares (100% of shares sold).
- Warrant Terms: Exercise price of $0.52 per share; exercisable immediately; expiration in 5.5 years.
- Net Proceeds: Approximately $591,000 after deducting placement agent fees and estimated offering expenses.
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds, plus warrants to purchase 68,344 shares (6% of shares sold) at $0.80 per share.
- Use of Proceeds: Funding clinical trials, maintaining/extending patent portfolio, and working capital.
Material Changes and Unusual Items
This filing represents a capital raise event rather than a periodic financial performance report. Consequently, there are no reported changes in revenue, profit, cash flow, or operating margins compared to prior periods. The primary material change is the dilution of existing shareholders through the issuance of new shares and warrants, and the increase in cash liquidity upon closing.
Guidance, Outlook, and Risks
- Outlook: Management intends to utilize proceeds to advance clinical trials and protect intellectual property.
- Closing Conditions: The offering is expected to close on or about November 20, 2023, subject to customary closing conditions.
- Regulatory Status: The warrants and placement agent warrants are unregistered and issued under Section 4(a)(2) of the Securities Act and/or Regulation D exemptions.
- Risks: The filing notes that the description of agreements is qualified by the full text of the exhibits attached to the filing.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected November 20, 2023) and confirmation of net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Monitor the impact of the 1,139,063 new shares and associated warrants on the company's fully diluted share count.
- Confirm the status of the clinical trials and patent portfolio extensions mentioned as the primary use of proceeds.